Novartis(US:NVS) Zhi Tong Cai Jing·2025-09-26 01:33Core Insights - Novartis announced positive data regarding its monoclonal antibody Kesimpta (ofatumumab) for relapsing multiple sclerosis (RMS), demonstrating sustained efficacy for up to 7 years [1][2] Group 1: Efficacy Data - In a 3b phase study (ARTIOS), patients who switched to Kesimpta after experiencing disease activity on other treatments showed a significantly low annualized relapse rate (ARR) of only 0.06 at 96 weeks [1] - Over 90% of participants in the ARTIOS study exhibited no evidence of disease activity (NEDA-3) as assessed by MRI [1] - In the ALITHIOS study, more than 90% of treatment-naive RMS patients achieved NEDA-3 by the seventh year, indicating the long-term effectiveness of Kesimpta [2] Group 2: Safety Profile - No new safety issues were observed in patients switching to Kesimpta, regardless of their previous disease-modifying therapy (DMT) [1][2] - The therapy demonstrated good safety characteristics in both the overall population and treatment-naive patients [2] Group 3: Product Information - Kesimpta is a fully humanized monoclonal antibody targeting CD20, approved by the FDA in 2020 for treating relapsing adult multiple sclerosis patients [2] - It is the first B-cell targeted therapy that allows patients to self-inject at home monthly using an auto-injector, enhancing disease management convenience [2]